Are physiological clonal expansion and maturation pathways a basis for discrepant behaviour of colon tumoral cell growth in response to the thiazolidinedione PPARgamma agonists?
Recently, anti-diabetic thiazolidinediones, pharmacological agonist ligands of peroxisome proliferator-activated receptor gamma (PPARgamma), have been shown to induce either protective or permissive effects towards colon epithelium tumoral cell growth. Several attractive explanations have been proposed but no final answer to these <conflicts in a nuclear family> is currently provided. It is not the purpose of the authors to bring this final answer but to offer another attractive hypothesis which might help our approach to explore further this exciting field of medical research.
Vamecq
J
J
National Institute of Health and Medical Research (French INSERM), Domaine du CERTIA, 59561 Villeneuve d'Ascq, France.
Latruffe
N
N
D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002999:Clone Cells / Q000187:drug effects / Q000473:pathology; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists* / Q000378:metabolism; D013844:Thiazoles / Q000494:pharmacology* / Q000627:therapeutic use; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000819:agonists* / Q000378:metabolism
D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; C089946:2,4-thiazolidinedione